Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.36 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a cautious optimism about the company's direction. They emphasized the importance of their ongoing projects.
Management expressed optimism about future developments.
They highlighted ongoing projects that could enhance growth.
The earnings report indicates that Soleno Therapeutics did not meet EPS expectations, but the stock rose by 15.49%. This increase may reflect investor optimism about future projects and management's positive outlook despite the lack of specific guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
APPFOLIO INC Class A
Mar 2, 2020